Renate Panzer‐Grümayer

CD371 cell surface expression: a unique feature of <i>DUX4</i>-rearranged acute lymphoblastic leukemia

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics

Rational Response-Adapted Risk Stratification and Treatment for Children with Late Bone Marrow Relapses of B-Cell Precursor Acute Lymphoblastic Leukaemia: A Report from the &lt;i&gt;ALL-REZ BFM&lt;/i&gt; Trial Group

Molecular characterization of acute lymphoblastic leukemia with high <i>CRLF2</i> gene expression in childhood

Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia

The Combination of MRD and Copy Number Alterations (CNAs) Defines an Ultra-High Risk Group of Children with Primary T-Lymphoblastic Leukemia (T-ALL)

Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

Treatment outcome of <scp><i>CRLF2</i></scp>‐rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the <scp>AIEOP</scp>‐<scp>BFM</scp> and <scp>UK NCRI</scp>‐<scp>CCLG</scp> study groups